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Background
This retrospective study was made with the purpose of
evaluating the rate of complete pathological response
(CPR) of the tumor and CPR of the axillary lymph nodes
in patients with Her2/neu dealt with preoperative sys-
temic treatment.
Materials and methods
We retrospectively reviewed thirty-three (n: 33) clinical
records of females with diagnosis of locally advanced
breast cancer with positive Her 2/neu receptors, which
was treated with preoperative chemotherapy in the Insti-
tute from January 2004 to December 2005. The median of
age was of 58 +/- 14 years (rank: 36–91 years). The initial
clinical stages were: IIA, n: 1 (3%); IIB, n: 3 (9%), IIIA, n:
19 (58%) and IIIB, n: 10 (30%). The initial nodal stage
were: N0, n: 5 (15%); N1, n: 9 (27%), and N2, n: 19
(58%). Twenty-one (64%) patients had both hormonal
ER and PR negatives. The combination of Anthracyclines
and Taxanes was prescribed in n: 17 (52%) and n: 8
(24%) received in addition neoadjuvant Trastuzumab
(Herceptin). A breast conservative surgery was performed
in four (n: 4) patients, the rest of patients a modified rad-
ical mastectomy was made. The median number of dis-
sected nodes was of 13 +/- 7 nodes (rank: 3–32) and
median of the percentage of metastasic nodes was of 15 +/
- 24% (rank: 0–72%).
Results
The rate of tumor CPR was achieved in 9/33 patients
(27%) and the rate of nodal CPR was noted in 11/33
patients (33%). The patients who received neoadjuvant
Trastuzumab had same tumor CPR and axillary lymph
node CPR of 38% (3/8). An 18% (6/33) of the patients
presented total CPR (tumor and nodal). The tumor or
axillary lymph nodes CPR was no associated with age, his-
tology, menopause status, initial clinical or nodal stage,
use of neoadjuvant Trastuzumab or the scheme of chem-
otherapy or the state of ER/PR. Sixty-six percent of com-
plete pathologic responders had negative axillary lymph
nodes compared to 21% of patients who did not have a
complete pathologic response (P = 0.013).
Conclusion
The rate of tumor and nodal CPR is within of the reported
in the literature. It is important to emphasize the promis-
ing benefit and the controversial role of preoperative Tras-
tuzumab in these patients. Others molecular biological
factors must be studied like favorable predicting of patho-
logical response.
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